首页 > 最新文献

Cancer diagnosis & prognosis最新文献

英文 中文
Colposcopically Directed Biopsy Before Ablative Treatment Versus Direct Ablative Treatment in Patients With Cervical Oncogenic HPV. 宫颈致癌型 HPV 患者在消融治疗前进行阴道镜引导活检与直接消融治疗的比较
Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10343
Diego Erasun, Ana Vazquez Delcampo, Alazne DE Castro, Alberto Munoz-Solano, José Schneider

Background/aim: In the past, the standard of care for women with abnormal cervical cytology has been the performance of colposcopically guided biopsy, followed by conization or large loop excision of the transition zone (LLETZ) where biopsy revealed pre-cancerous or cancerous areas. More straightforward protocols are emerging which advocate performing LLETZ in all women with highly suspicious cytology, suspicious colposcopic impression, or the presence of high-risk oncogenic human papilloma virus (HPV) strains in their cervical swabs. This, theoretically, would reduce the rate of false-negative diagnoses, but at the price of overtreating a significant number of healthy women.

Patients and methods: We retrospectively analyzed cervical cancer screening protocols in two large cohorts of women with high-risk HPV. The study compared outcomes between patients undergoing a colposcopically directed biopsy before LLETZ (n=683) and those proceeding directly to LLETZ without a biopsy (n=136). The primary focus was to assess whether intervening biopsies would reduce unnecessary ablative procedures without compromising the detection of high-grade lesions.

Results: The biopsy group had a high false-negative rate, with several high-grade lesions (CIN3) and a case of invasive cancer initially underdiagnosed. Conversely, the direct-to-LLETZ approach, while ensuring no high-grade lesions were missed, led to overtreatment of lower grade lesions.

Conclusion: These findings raise concern about the reliance on biopsy results for treatment decisions. Neither protocol was entirely satisfactory, although the more aggressive one avoided the potentially life-threatening consequence of false-negative results. Further research is mandatory to accurately diagnose all cases requiring aggressive treatment, without subjecting healthy women to ablative treatments they do not need.

背景/目的:过去,宫颈细胞学异常妇女的标准治疗方法是在阴道镜引导下进行活检,然后在活检发现癌前病变或癌变区域时进行锥切术或过渡区大环切除术(LLETZ)。目前出现了一些更直接的方案,主张对所有细胞学高度可疑、阴道镜检查结果可疑或宫颈拭子中存在高危致癌人类乳头瘤病毒(HPV)株的妇女进行 LLETZ。从理论上讲,这将降低假阴性诊断率,但代价是要对大量健康妇女进行过度治疗:我们回顾性地分析了两组高危 HPV 妇女的宫颈癌筛查方案。研究比较了在LLETZ前接受阴道镜引导活检的患者(683人)和不进行活检直接接受LLETZ的患者(136人)的治疗效果。主要重点是评估介入活检是否会减少不必要的消融手术,同时又不影响高级别病变的检测:结果:活检组的假阴性率很高,有几个高级别病变(CIN3)和一例浸润性癌症最初诊断不足。相反,直达LLETZ方法在确保不漏诊高级别病变的同时,却导致了对低级别病变的过度治疗:结论:这些发现引起了人们对依赖活检结果做出治疗决定的担忧。这两种方案都不尽如人意,尽管更激进的方案避免了假阴性结果可能造成的生命危险。必须开展进一步研究,以准确诊断所有需要积极治疗的病例,同时避免让健康女性接受她们不需要的消融治疗。
{"title":"Colposcopically Directed Biopsy Before Ablative Treatment Versus Direct Ablative Treatment in Patients With Cervical Oncogenic HPV.","authors":"Diego Erasun, Ana Vazquez Delcampo, Alazne DE Castro, Alberto Munoz-Solano, José Schneider","doi":"10.21873/cdp.10343","DOIUrl":"10.21873/cdp.10343","url":null,"abstract":"<p><strong>Background/aim: </strong>In the past, the standard of care for women with abnormal cervical cytology has been the performance of colposcopically guided biopsy, followed by conization or large loop excision of the transition zone (LLETZ) where biopsy revealed pre-cancerous or cancerous areas. More straightforward protocols are emerging which advocate performing LLETZ in all women with highly suspicious cytology, suspicious colposcopic impression, or the presence of high-risk oncogenic human papilloma virus (HPV) strains in their cervical swabs. This, theoretically, would reduce the rate of false-negative diagnoses, but at the price of overtreating a significant number of healthy women.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed cervical cancer screening protocols in two large cohorts of women with high-risk HPV. The study compared outcomes between patients undergoing a colposcopically directed biopsy before LLETZ (n=683) and those proceeding directly to LLETZ without a biopsy (n=136). The primary focus was to assess whether intervening biopsies would reduce unnecessary ablative procedures without compromising the detection of high-grade lesions.</p><p><strong>Results: </strong>The biopsy group had a high false-negative rate, with several high-grade lesions (CIN3) and a case of invasive cancer initially underdiagnosed. Conversely, the direct-to-LLETZ approach, while ensuring no high-grade lesions were missed, led to overtreatment of lower grade lesions.</p><p><strong>Conclusion: </strong>These findings raise concern about the reliance on biopsy results for treatment decisions. Neither protocol was entirely satisfactory, although the more aggressive one avoided the potentially life-threatening consequence of false-negative results. Further research is mandatory to accurately diagnose all cases requiring aggressive treatment, without subjecting healthy women to ablative treatments they do not need.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Circular Stapler Size on the Risk of Anastomotic Complications in Patients With Left-sided Colorectal Cancer: A Propensity Score-matched Study. 左侧结直肠癌患者吻合口并发症风险与环形订书机尺寸的影响:倾向评分匹配研究
Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10356
Masatsune Shibutani, Tatsunari Fukuoka, Yasuhito Iseki, Hiroaki Kasashima, Yuki Seki, Kiyoshi Maeda

Background/aim: The present study examined the impact of circular stapler size on anastomotic complications, including leakage and stricture in patients undergoing double-stapling technique (DST) anastomosis for left-sided colon or rectal cancer.

Patients and methods: A total of 403 patients were enrolled in this study, with circular stapler sizes  of 25, 28, and 29 mm.

Results: A small circular stapler (25 mm) was used in 170 cases (42.2%), and a medium-sized circular stapler (28/29 mm) was used in 233 cases (57.8%). After propensity score matching, there was no marked difference in the incidence of anastomotic leakage/stricture between the groups (13.9% vs. 10.9%, 3.0% vs. 1.0%, respectively).

Conclusion: The size of the circular stapler was not associated with the incidence of anastomotic leakage or stricture in this cohort.

背景/目的:本研究探讨了在接受双缝合技术(DST)吻合术治疗左侧结肠癌或直肠癌的患者中,圆形订书机尺寸对吻合口并发症(包括渗漏和狭窄)的影响:共有 403 名患者参与了这项研究,圆形订书机的尺寸为 25、28 和 29 毫米:结果:170 例(42.2%)使用了小型圆形订书机(25 毫米),233 例(57.8%)使用了中型圆形订书机(28/29 毫米)。经过倾向得分匹配后,两组吻合口漏/狭窄的发生率没有明显差异(分别为 13.9% 对 10.9%,3.0% 对 1.0%):结论:在这组患者中,圆形订书机的大小与吻合口漏或狭窄的发生率无关。
{"title":"Impact of Circular Stapler Size on the Risk of Anastomotic Complications in Patients With Left-sided Colorectal Cancer: A Propensity Score-matched Study.","authors":"Masatsune Shibutani, Tatsunari Fukuoka, Yasuhito Iseki, Hiroaki Kasashima, Yuki Seki, Kiyoshi Maeda","doi":"10.21873/cdp.10356","DOIUrl":"10.21873/cdp.10356","url":null,"abstract":"<p><strong>Background/aim: </strong>The present study examined the impact of circular stapler size on anastomotic complications, including leakage and stricture in patients undergoing double-stapling technique (DST) anastomosis for left-sided colon or rectal cancer.</p><p><strong>Patients and methods: </strong>A total of 403 patients were enrolled in this study, with circular stapler sizes  of 25, 28, and 29 mm.</p><p><strong>Results: </strong>A small circular stapler (25 mm) was used in 170 cases (42.2%), and a medium-sized circular stapler (28/29 mm) was used in 233 cases (57.8%). After propensity score matching, there was no marked difference in the incidence of anastomotic leakage/stricture between the groups (13.9% vs. 10.9%, 3.0% vs. 1.0%, respectively).</p><p><strong>Conclusion: </strong>The size of the circular stapler was not associated with the incidence of anastomotic leakage or stricture in this cohort.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Role of Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios in Patients Irradiated for Glioblastoma Multiforme. 多形性胶质母细胞瘤放射治疗患者的血小板淋巴细胞比率和中性粒细胞淋巴细胞比率的预后作用
Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10340
Oksana Zemskova, Nathan Y Yu, Anastassia Löser, Jan Leppert, Dirk Rades

Background/aim: Previous studies suggested pre-operative platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) to be predictive factors in patients with glioblastoma multiforme (GBM). This study investigated the prognostic role of PLR and NLR prior to or at the beginning of radiotherapy.

Patients and methods: In 80 patients with GBM receiving conventionally fractionated radiotherapy plus concurrent temozolomide following resection or biopsy, 12 factors including PLR and NLR were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS).

Results: On multivariable analyses, PLR ≤150, Karnofsky performance score (KPS) 90-100, and O6-methylguanine-DNA methyltransferase promoter methylation were significantly associated with improved PFS. Single lesion, KPS 90-100, and adjuvant chemotherapy were significantly associated with OS; PLR ≤150 showed a trend. NLR ≤3 showed a trend for associations with PFS and OS on univariable analyses.

Conclusion: PLR prior to or at the beginning of radiotherapy was associated with treatment outcomes in patients irradiated for GBM and should be considered in future clinical trials.

背景/目的:先前的研究表明,术前血小板与淋巴细胞比值(PLR)和中性粒细胞与淋巴细胞比值(NLR)是多形性胶质母细胞瘤(GBM)患者的预测因素。本研究调查了 PLR 和 NLR 在放疗之前或开始时的预后作用:对80名在切除术或活检后接受常规分次放疗并同时使用替莫唑胺的GBM患者进行了无进展生存期(PFS)和总生存期(OS)的回顾性评估,评估了包括PLR和NLR在内的12个因素:多变量分析显示,PLR≤150、Karnofsky表现评分(KPS)90-100和O6-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化与PFS改善显著相关。单病灶、KPS 90-100 和辅助化疗与 OS 显著相关;PLR ≤150 显示出一种趋势。在单变量分析中,NLR≤3显示出与PFS和OS相关的趋势:结论:放疗前或放疗开始时的PLR与GBM患者的治疗效果有关,在未来的临床试验中应加以考虑。
{"title":"Prognostic Role of Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios in Patients Irradiated for Glioblastoma Multiforme.","authors":"Oksana Zemskova, Nathan Y Yu, Anastassia Löser, Jan Leppert, Dirk Rades","doi":"10.21873/cdp.10340","DOIUrl":"10.21873/cdp.10340","url":null,"abstract":"<p><strong>Background/aim: </strong>Previous studies suggested pre-operative platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) to be predictive factors in patients with glioblastoma multiforme (GBM). This study investigated the prognostic role of PLR and NLR prior to or at the beginning of radiotherapy.</p><p><strong>Patients and methods: </strong>In 80 patients with GBM receiving conventionally fractionated radiotherapy plus concurrent temozolomide following resection or biopsy, 12 factors including PLR and NLR were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>On multivariable analyses, PLR ≤150, Karnofsky performance score (KPS) 90-100, and O6-methylguanine-DNA methyltransferase promoter methylation were significantly associated with improved PFS. Single lesion, KPS 90-100, and adjuvant chemotherapy were significantly associated with OS; PLR ≤150 showed a trend. NLR ≤3 showed a trend for associations with PFS and OS on univariable analyses.</p><p><strong>Conclusion: </strong>PLR prior to or at the beginning of radiotherapy was associated with treatment outcomes in patients irradiated for GBM and should be considered in future clinical trials.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Combination of Methionine Restriction and Docetaxel Synergistically Arrests Androgen-independent Prostate Cancer But Not Normal Cells. 甲硫氨酸限制与多西他赛的结合能协同抑制雄激素依赖性前列腺癌,但不能抑制正常细胞。
Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10339
Kohei Mizuta, Ryosuke Mori, Qinghong Han, Sei Morinaga, Motokazu Sato, Byung Mo Kang, Michael Bouvet, Yasunori Tome, Kotaro Nishida, Robert M Hoffman

Background/aim: Androgen-independent prostate cancer (AIPC) is resistant to androgen-depletion therapy and is a recalcitrant disease. Docetaxel is the first-line treatment for AIPC, but has limited efficacy and severe side-effects. All cancers are methionine-addicted, which is termed the Hoffman effect. Recombinant methioninase (rMETase) targets methionine addiction. The purpose of the present study was to determine if the combination of docetaxel and rMETase is effective for AIPC.

Materials and methods: The half-maximal inhibitory concentrations (IC50) of docetaxel and rMETase alone were determined for the human AIPC cell line PC-3 and Hs27 normal human fibroblasts in vitro. The synergistic efficacy for PC-3 and Hs27 using the combination of docetaxel and rMETase at their IC50s for PC-3 was determined.

Results: The IC50 of docetaxel for PC-3 and for Hs27 was 0.72 nM and 0.94 nM, respectively. The IC50 of rMETase for PC-3 and for Hs27 was 0.67 U/ml and 0.76 U/ml, respectively. The combination of docetaxel and rMETase was synergistic for PC-3 but not Hs27 cells.

Conclusion: The combination of a relatively low concentration of docetaxel and rMETase was synergistic and effective for AIPC. The present results also suggest that the effective concentration of docetaxel can be reduced by using rMETase, which may reduce toxicity. The present results also suggest the future clinical potential of the combination of docetaxel and rMETase for AIPC.

背景/目的:雄激素依赖性前列腺癌(AIPC)对雄激素耗竭疗法耐药,是一种顽固性疾病。多西他赛是治疗 AIPC 的一线疗法,但疗效有限且副作用严重。所有癌症都会对蛋氨酸上瘾,这被称为霍夫曼效应。重组蛋氨酸酵素(rMETase)可针对蛋氨酸成瘾。本研究的目的是确定多西他赛和rMET酶联合使用是否对AIPC有效:在体外测定了多西他赛和rMET酶单独对人类AIPC细胞系PC-3和Hs27正常人成纤维细胞的半数最大抑制浓度(IC50)。在多西他赛和 rMETase 对 PC-3 和 Hs27 的 IC50s 浓度下,确定了多西他赛和 rMETase 组合对 PC-3 和 Hs27 的协同疗效:结果:多西他赛对 PC-3 和 Hs27 的 IC50 分别为 0.72 nM 和 0.94 nM。rMETase对PC-3和Hs27的IC50分别为0.67 U/ml和0.76 U/ml。多西他赛和 rMETase 的组合对 PC-3 细胞有协同作用,但对 Hs27 细胞无协同作用:结论:相对低浓度的多西他赛和 rMET 酶联合使用对 AIPC 有协同作用且有效。本研究结果还表明,使用 rMETase 可以降低多西他赛的有效浓度,从而减少毒性。本研究结果还表明,多西他赛和rMET酶联合治疗AIPC在未来具有临床潜力。
{"title":"The Combination of Methionine Restriction and Docetaxel Synergistically Arrests Androgen-independent Prostate Cancer But Not Normal Cells.","authors":"Kohei Mizuta, Ryosuke Mori, Qinghong Han, Sei Morinaga, Motokazu Sato, Byung Mo Kang, Michael Bouvet, Yasunori Tome, Kotaro Nishida, Robert M Hoffman","doi":"10.21873/cdp.10339","DOIUrl":"10.21873/cdp.10339","url":null,"abstract":"<p><strong>Background/aim: </strong>Androgen-independent prostate cancer (AIPC) is resistant to androgen-depletion therapy and is a recalcitrant disease. Docetaxel is the first-line treatment for AIPC, but has limited efficacy and severe side-effects. All cancers are methionine-addicted, which is termed the Hoffman effect. Recombinant methioninase (rMETase) targets methionine addiction. The purpose of the present study was to determine if the combination of docetaxel and rMETase is effective for AIPC.</p><p><strong>Materials and methods: </strong>The half-maximal inhibitory concentrations (IC<sub>50</sub>) of docetaxel and rMETase alone were determined for the human AIPC cell line PC-3 and Hs27 normal human fibroblasts in vitro. The synergistic efficacy for PC-3 and Hs27 using the combination of docetaxel and rMETase at their IC<sub>50</sub>s for PC-3 was determined.</p><p><strong>Results: </strong>The IC<sub>50</sub> of docetaxel for PC-3 and for Hs27 was 0.72 nM and 0.94 nM, respectively. The IC<sub>50</sub> of rMETase for PC-3 and for Hs27 was 0.67 U/ml and 0.76 U/ml, respectively. The combination of docetaxel and rMETase was synergistic for PC-3 but not Hs27 cells.</p><p><strong>Conclusion: </strong>The combination of a relatively low concentration of docetaxel and rMETase was synergistic and effective for AIPC. The present results also suggest that the effective concentration of docetaxel can be reduced by using rMETase, which may reduce toxicity. The present results also suggest the future clinical potential of the combination of docetaxel and rMETase for AIPC.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review. 抗 EGFR 抗体导致低镁血症的癌症患者补充镁的疗效:系统回顾
Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10337
Taigo Kato, Takahisa Kawaguchi, Taro Funakoshi, Yutaka Fujiwara, Yoshinari Yasuda, Yuichi Ando

Background/aim: Hypomagnesemia is a common side effect of anti-epidermal growth factor receptor (EGFR) antibodies, which may lead to arrhythmia. However, there are no evidence-based guidelines for magnesium (Mg) supplementation in the management of hypomagnesemia in patients with anti-EGFR antibodies. Therefore, we performed a systematic review to address clinical questions regarding these cancer patients.

Materials and methods: Three electronic databases were searched for articles published until June 18, 2021. The main outcomes used were "anti-EGFR antibody" and "hypomagnesemia".

Results: After screening 78 references in PubMed, Cochrane Library, and ICHUSHI-web databases, three studies were included in the review. One study revealed the effectiveness of Mg supplementation in the management of hypomagnesemia in patients receiving cetuximab. However, no studies have investigated whether correcting hypomagnesemia can lead to the suppression of arrhythmias as a clinical outcome.

Conclusion: Weak evidence suggests that Mg supplementation, as a preventive measure when developing hypomagnesemia following the initiation of anti-EGFR antibody therapy, may prevent the worsening of hypomagnesemia, and subsequently prevent associated arrhythmia occurrence.

背景/目的:低镁血症是抗表皮生长因子受体(EGFR)抗体的常见副作用,可能导致心律失常。然而,目前还没有关于抗表皮生长因子受体(EGFR)抗体患者在治疗低镁血症时补充镁(Mg)的循证指南。因此,我们进行了一项系统性综述,以解决有关这些癌症患者的临床问题:检索了三个电子数据库中截至 2021 年 6 月 18 日发表的文章。主要结果为 "抗EGFR抗体 "和 "低镁血症":结果:在PubMed、Cochrane Library和ICHUSHI-web数据库中筛选出78篇参考文献后,有三项研究被纳入综述。其中一项研究表明,在接受西妥昔单抗治疗的患者中,补充镁元素可有效控制低镁血症。然而,没有研究调查了纠正低镁血症是否能抑制心律失常这一临床结果:微弱的证据表明,在开始接受抗表皮生长因子受体(EGFR)抗体治疗后出现低镁血症时,作为预防措施补充镁元素可防止低镁血症恶化,进而防止相关心律失常的发生。
{"title":"Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.","authors":"Taigo Kato, Takahisa Kawaguchi, Taro Funakoshi, Yutaka Fujiwara, Yoshinari Yasuda, Yuichi Ando","doi":"10.21873/cdp.10337","DOIUrl":"10.21873/cdp.10337","url":null,"abstract":"<p><strong>Background/aim: </strong>Hypomagnesemia is a common side effect of anti-epidermal growth factor receptor (EGFR) antibodies, which may lead to arrhythmia. However, there are no evidence-based guidelines for magnesium (Mg) supplementation in the management of hypomagnesemia in patients with anti-EGFR antibodies. Therefore, we performed a systematic review to address clinical questions regarding these cancer patients.</p><p><strong>Materials and methods: </strong>Three electronic databases were searched for articles published until June 18, 2021. The main outcomes used were \"anti-EGFR antibody\" and \"hypomagnesemia\".</p><p><strong>Results: </strong>After screening 78 references in PubMed, Cochrane Library, and ICHUSHI-web databases, three studies were included in the review. One study revealed the effectiveness of Mg supplementation in the management of hypomagnesemia in patients receiving cetuximab. However, no studies have investigated whether correcting hypomagnesemia can lead to the suppression of arrhythmias as a clinical outcome.</p><p><strong>Conclusion: </strong>Weak evidence suggests that Mg supplementation, as a preventive measure when developing hypomagnesemia following the initiation of anti-EGFR antibody therapy, may prevent the worsening of hypomagnesemia, and subsequently prevent associated arrhythmia occurrence.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparities in Trend of Renal Cell Carcinoma Mortality in the United States. 美国肾细胞癌死亡率趋势的差异。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10317
Sishir Doddi, M Hammad Rashid

Background/aim: Renal cell carcinoma (RCC) accounts for 90% of malignant neoplasms of the kidney.

Patients and methods: In this report, the CDC WONDER database was accessed to retrieve age-adjusted mortality data from 1999 to 2020 due to RCC, defined as ICD-10 Code: C64 Malignant neoplasm of kidney except renal pelvis, for various demographics to investigate trends and potential disparities.

Results: In 2020, the overall age-adjusted mortality rate (AAMR) due to RCC in the USA was 42.4 per 1,000,000. The average annual percent change (AAPC) for the USA from 1999 to 2020 was -0.6%. Notably, in 2020, men had a higher AAMR than women, 63.9 compared to 25.7, and a significant difference in AAPC trend was identified between men (-0.5%) and women (-1.0%). When investigating trends according to race in 2020, the Asian population displayed the lowest AAMR at 18.9. When determining AAPC from 1999 to 2020 according to race group, the American Indian group demonstrated the greatest decline in AAPC at -1.3%, followed by the Black (-1.2%) and White populations (-0.5%). The Asian population did not exhibit a significant AAPC. Moreover, the rates between these three groups were statistically significantly different- indicating disparities in trend based on race.

Conclusion: This investigation assesses the AAMR for different demographic groups of the USA population to identify disparities and guide resource allocation strategies.

背景/目的:肾细胞癌(RCC)占肾脏恶性肿瘤的90%:肾细胞癌(RCC)占肾脏恶性肿瘤的90%:在本报告中,我们访问了中国疾病预防控制中心WONDER数据库,检索了1999年至2020年因RCC(定义为ICD-10代码:C64肾脏恶性肿瘤,肾盂除外)导致的年龄调整后死亡率数据:C64肾脏恶性肿瘤(肾盂除外),以调查各种人口统计学数据的趋势和潜在差异:结果:2020 年,美国因 RCC 导致的年龄调整后总死亡率 (AAMR) 为 42.4‰。从 1999 年到 2020 年,美国的年均百分比变化(AAPC)为-0.6%。值得注意的是,2020 年男性的年平均死亡率高于女性(63.9:25.7),而且男性(-0.5%)和女性(-1.0%)的年平均变化趋势存在显著差异。在研究 2020 年的种族趋势时,亚裔人口的 AAMR 最低,为 18.9。在根据种族群体确定 1999 年至 2020 年的 AAPC 时,美国印第安人群体的 AAPC 下降幅度最大,为-1.3%,其次是黑人(-1.2%)和白人(-0.5%)。亚裔人口的 AAPC 下降幅度不大。此外,这三个群体之间的比率在统计学上存在显著差异,表明不同种族的趋势存在差异:这项调查评估了美国不同人口群体的亚裔美国人死亡率,以确定差异并指导资源分配策略。
{"title":"Disparities in Trend of Renal Cell Carcinoma Mortality in the United States.","authors":"Sishir Doddi, M Hammad Rashid","doi":"10.21873/cdp.10317","DOIUrl":"https://doi.org/10.21873/cdp.10317","url":null,"abstract":"<p><strong>Background/aim: </strong>Renal cell carcinoma (RCC) accounts for 90% of malignant neoplasms of the kidney.</p><p><strong>Patients and methods: </strong>In this report, the CDC WONDER database was accessed to retrieve age-adjusted mortality data from 1999 to 2020 due to RCC, defined as ICD-10 Code: C64 Malignant neoplasm of kidney except renal pelvis, for various demographics to investigate trends and potential disparities.</p><p><strong>Results: </strong>In 2020, the overall age-adjusted mortality rate (AAMR) due to RCC in the USA was 42.4 per 1,000,000. The average annual percent change (AAPC) for the USA from 1999 to 2020 was -0.6%. Notably, in 2020, men had a higher AAMR than women, 63.9 compared to 25.7, and a significant difference in AAPC trend was identified between men (-0.5%) and women (-1.0%). When investigating trends according to race in 2020, the Asian population displayed the lowest AAMR at 18.9. When determining AAPC from 1999 to 2020 according to race group, the American Indian group demonstrated the greatest decline in AAPC at -1.3%, followed by the Black (-1.2%) and White populations (-0.5%). The Asian population did not exhibit a significant AAPC. Moreover, the rates between these three groups were statistically significantly different- indicating disparities in trend based on race.</p><p><strong>Conclusion: </strong>This investigation assesses the AAMR for different demographic groups of the USA population to identify disparities and guide resource allocation strategies.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiological Cutoff Values for Diagnosis of Lymph Node Metastasis in Colorectal Cancer With Multilevel Analysis. 利用多层次分析诊断结直肠癌淋巴结转移的放射学临界值
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10329
Yukitoshi Todate, Toshihiko Takada, Michitaka Honda, Teppei Miyakawa, Ryuya Yamamoto, Satoshi Toshiyama, Eiichi Nakao, Ryutaro Mashiko, Hirohito Kakinuma, Hidetaka Kawamura, Hisashi Yamaguchi, Yoshiaki Takagawa, Koji Kono

Background/aim: A cutoff value for lymph node diameter in colorectal cancer lymph node metastases has not been established. This prospective study aimed to investigate the direct association between swollen lymph nodes identified on preoperative computed tomography (CT) and pathological findings and proposed a cutoff value.

Patients and methods: We enrolled patients scheduled to undergo curative surgery with lymph node dissection for colorectal adenocarcinoma who underwent preoperative contrast-enhanced CT and had swollen lymph nodes ≥7 mm in diameter. Two gastrointestinal surgeons intraoperatively identified the target lymph nodes to assess the association between lymph node diameter and pathological findings. The diagnostic performance for lymph node metastasis was determined using multi-level logistic modelling.

Results: A total of 109 patients were enrolled, and 225 swollen lymph nodes were pathologically evaluated. Using a cutoff value of ≥9 mm for the short diameter, the positive and negative predictive values, sensitivity, and specificity were 100.0% (99.6%-100.0%), 99.9% (99.1%-100.0%), 62.0% (45.6%-76.0%), and 84.9% (67.0%-94.0%), respectively.

Conclusion: The cutoff value for improving the positive predictive value for the preoperative lymph node metastasis diagnosis in colorectal cancer patients should be at least 9 mm in diameter.

背景/目的:大肠癌淋巴结转移中淋巴结直径的临界值尚未确定。这项前瞻性研究旨在调查术前计算机断层扫描(CT)发现的淋巴结肿大与病理结果之间的直接联系,并提出一个临界值:我们招募了计划接受治愈性手术并进行淋巴结清扫的结直肠腺癌患者,这些患者在术前接受了造影剂增强 CT 检查,且淋巴结肿大的直径≥7 毫米。两名胃肠外科医生在术中确定了目标淋巴结,以评估淋巴结直径与病理结果之间的关联。采用多级逻辑模型确定淋巴结转移的诊断结果:共有109名患者入组,对225个肿大淋巴结进行了病理评估。以短径≥9毫米为临界值,阳性和阴性预测值、敏感性和特异性分别为100.0%(99.6%-100.0%)、99.9%(99.1%-100.0%)、62.0%(45.6%-76.0%)和84.9%(67.0%-94.0%):提高大肠癌患者术前淋巴结转移诊断阳性预测值的临界值至少应为直径 9 毫米。
{"title":"Radiological Cutoff Values for Diagnosis of Lymph Node Metastasis in Colorectal Cancer With Multilevel Analysis.","authors":"Yukitoshi Todate, Toshihiko Takada, Michitaka Honda, Teppei Miyakawa, Ryuya Yamamoto, Satoshi Toshiyama, Eiichi Nakao, Ryutaro Mashiko, Hirohito Kakinuma, Hidetaka Kawamura, Hisashi Yamaguchi, Yoshiaki Takagawa, Koji Kono","doi":"10.21873/cdp.10329","DOIUrl":"https://doi.org/10.21873/cdp.10329","url":null,"abstract":"<p><strong>Background/aim: </strong>A cutoff value for lymph node diameter in colorectal cancer lymph node metastases has not been established. This prospective study aimed to investigate the direct association between swollen lymph nodes identified on preoperative computed tomography (CT) and pathological findings and proposed a cutoff value.</p><p><strong>Patients and methods: </strong>We enrolled patients scheduled to undergo curative surgery with lymph node dissection for colorectal adenocarcinoma who underwent preoperative contrast-enhanced CT and had swollen lymph nodes ≥7 mm in diameter. Two gastrointestinal surgeons intraoperatively identified the target lymph nodes to assess the association between lymph node diameter and pathological findings. The diagnostic performance for lymph node metastasis was determined using multi-level logistic modelling.</p><p><strong>Results: </strong>A total of 109 patients were enrolled, and 225 swollen lymph nodes were pathologically evaluated. Using a cutoff value of ≥9 mm for the short diameter, the positive and negative predictive values, sensitivity, and specificity were 100.0% (99.6%-100.0%), 99.9% (99.1%-100.0%), 62.0% (45.6%-76.0%), and 84.9% (67.0%-94.0%), respectively.</p><p><strong>Conclusion: </strong>The cutoff value for improving the positive predictive value for the preoperative lymph node metastasis diagnosis in colorectal cancer patients should be at least 9 mm in diameter.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Analysis of External and Internal Radiotherapy- Dependent Plans in Patients with Gynecological Cancer. 妇科癌症患者的外照射和内照射放疗计划对比分析
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10331
Panagiotis Vourtsas, Kyrillos Sarris, Nikolaos Giakoumakis, Georgia Kolitsi, Kostas Kyprianou, Sofianiki Mastronikoli, Evangelos Tsiambas, Dimitrios Peschos, Dimitrios Kardamakis, Georgios Androutsopoulos, Despina Spyropoulou

Background/aim: Radiotherapy plays a key role in the treatment of gynecological cancer. Modern radiotherapy techniques with external beams (e-RT) are applied in a broad spectrum of gynecological cancer cases. However, high radiation doses, affecting normal tissue adjacent to cancer, represent the main disadvantage of e-RT regimens. For this reason, brachytherapy (BT), an internal beam-based technique (i-RT), is suggested following e-RT. Our purpose was to compare e-RT plans using volumetric-modulated arc therapy (VMAT) with those using 3D conformal techniques (3D-CRT) and compare BT plans guided by 3D or 2D imaging based on the potential corresponding toxicity levels.

Materials and methods: In this preliminary, non-randomized comparative retrospective study, 15 females suffering gynecological cancer were enrolled. Modern e-RT and i-RT (BT) techniques were applied.

Results: Concerning e-RT, D95/D99/rectum 2cc/bladder 2cc and small intestine 2cc were measured and compared; in i-RT, rectum 2cc/bladder 2cc were measured and compared. The median dose to the planning target volume in VMAT was 97.4 Gy compared with 92.9 Gy in 3D-CRT. Τhe rectum received almost 5 Gy less in VMAT compared to 3D-CRT (median of 43.5 Gy vs. 48.6 Gy; p=0.001). In the bladder, dose differences were minimal, while the small intestine received 47.6 Gy in VMAT (p=0.001). Regarding 3D-BT, the rectum received 63.1 Gy compared with 49.9 Gy (p=0.009) in 2D-BT. Concerning the bladder, mean 2D-BT and 3D-BT doses were 71.9 and 65 Gy, respectively, differing non-significantly.

Conclusion: VMAT was found to be superior to 3D-CRT, especially in dose distribution, volume coverage and protection of critical organs. Similarly, 3D-BT should be preferred over 2D-BT due to critical advantages.

背景/目的:放疗在妇科癌症治疗中发挥着关键作用。外照射(e-RT)现代放疗技术广泛应用于妇科癌症病例。然而,高辐射剂量会影响癌症附近的正常组织,这是电子放射治疗方案的主要缺点。因此,在采用电子放射治疗后,建议采用近距离放射治疗(BT),这是一种基于内照射的技术(i-RT)。我们的目的是比较使用容积调制弧治疗(VMAT)的电子放射治疗方案和使用三维适形技术(3D-CRT)的电子放射治疗方案,并根据潜在的相应毒性水平比较三维或二维成像引导的近距离放射治疗方案:在这项初步的非随机回顾性比较研究中,共纳入了15名患有妇科癌症的女性。研究采用了现代 e-RT 和 i-RT (BT) 技术:结果:在e-RT中,测量并比较了D95/D99/直肠2cc/膀胱2cc和小肠2cc;在i-RT中,测量并比较了直肠2cc/膀胱2cc。VMAT 规划靶体积的中位剂量为 97.4 Gy,而 3D-CRT 为 92.9 Gy。与 3D-CRT 相比,直肠在 VMAT 中的剂量减少了近 5 Gy(中位数为 43.5 Gy 对 48.6 Gy;P=0.001)。膀胱的剂量差异很小,而小肠在 VMAT 中的剂量为 47.6 Gy(p=0.001)。在 3D-BT 中,直肠的剂量为 63.1 Gy,而 2D-BT 为 49.9 Gy(P=0.009)。膀胱方面,2D-BT 和 3D-BT 的平均剂量分别为 71.9 Gy 和 65 Gy,差异不显著:结论:VMAT优于3D-CRT,尤其是在剂量分布、容积覆盖和保护重要器官方面。结论:VMAT 在剂量分布、容积覆盖和保护重要器官方面更胜一筹。同样,3D-BT 也因其关键优势而优于 2D-BT。
{"title":"Comparative Analysis of External and Internal Radiotherapy- Dependent Plans in Patients with Gynecological Cancer.","authors":"Panagiotis Vourtsas, Kyrillos Sarris, Nikolaos Giakoumakis, Georgia Kolitsi, Kostas Kyprianou, Sofianiki Mastronikoli, Evangelos Tsiambas, Dimitrios Peschos, Dimitrios Kardamakis, Georgios Androutsopoulos, Despina Spyropoulou","doi":"10.21873/cdp.10331","DOIUrl":"https://doi.org/10.21873/cdp.10331","url":null,"abstract":"<p><strong>Background/aim: </strong>Radiotherapy plays a key role in the treatment of gynecological cancer. Modern radiotherapy techniques with external beams (e-RT) are applied in a broad spectrum of gynecological cancer cases. However, high radiation doses, affecting normal tissue adjacent to cancer, represent the main disadvantage of e-RT regimens. For this reason, brachytherapy (BT), an internal beam-based technique (i-RT), is suggested following e-RT. Our purpose was to compare e-RT plans using volumetric-modulated arc therapy (VMAT) with those using 3D conformal techniques (3D-CRT) and compare BT plans guided by 3D or 2D imaging based on the potential corresponding toxicity levels.</p><p><strong>Materials and methods: </strong>In this preliminary, non-randomized comparative retrospective study, 15 females suffering gynecological cancer were enrolled. Modern e-RT and i-RT (BT) techniques were applied.</p><p><strong>Results: </strong>Concerning e-RT, D95/D99/rectum 2cc/bladder 2cc and small intestine 2cc were measured and compared; in i-RT, rectum 2cc/bladder 2cc were measured and compared. The median dose to the planning target volume in VMAT was 97.4 Gy compared with 92.9 Gy in 3D-CRT. Τhe rectum received almost 5 Gy less in VMAT compared to 3D-CRT (median of 43.5 Gy vs. 48.6 Gy; p=0.001). In the bladder, dose differences were minimal, while the small intestine received 47.6 Gy in VMAT (p=0.001). Regarding 3D-BT, the rectum received 63.1 Gy compared with 49.9 Gy (p=0.009) in 2D-BT. Concerning the bladder, mean 2D-BT and 3D-BT doses were 71.9 and 65 Gy, respectively, differing non-significantly.</p><p><strong>Conclusion: </strong>VMAT was found to be superior to 3D-CRT, especially in dose distribution, volume coverage and protection of critical organs. Similarly, 3D-BT should be preferred over 2D-BT due to critical advantages.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transforming 'Junk' DNA into Cancer Warriors: The Role of Pseudogenes in Hepatocellular Carcinoma. 将 "垃圾 "DNA 变成癌症战士:假基因在肝细胞癌中的作用。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10311
Chugh Kritika

In the dynamic landscape of hepatocellular carcinoma (HCC) or the liver cancer research, pseudogenes have emerged from the shadows of genetic obscurity to become central figures, significantly influencing the disease molecular development and clinical trajectory. This review explores a transformative shift in perspective, recognizing pseudogenes not as genetic remnants without function, but as critical regulators in the molecular underpinnings of HCC. Engaging in complex interactions such as microRNA sponging, gene expression modulation, and signaling pathway disruptions, pseudogenes orchestrate a part of the molecular complexity driving tumor genesis, progression, and drug resistance in the liver cancer. Their unique expression patterns in hepatoma tissues herald new opportunities for early HCC detection, offering insights into patient prognosis, and identifying novel targets for therapeutic intervention of this disease. Such advancements underscore the importance of pseudogenes in enriching our understanding and management of HCC, paving the way for more effective diagnostic strategies and targeted therapies in the ongoing battle against this challenging malignancy.

在肝细胞癌(HCC)或肝癌研究的动态图景中,假基因已从遗传学默默无闻的阴影中脱颖而出,成为核心人物,对疾病的分子发展和临床轨迹产生了重大影响。这篇综述探讨了视角的转变,认识到假基因不是没有功能的基因残余,而是 HCC 分子基础的关键调控因子。假基因参与了复杂的相互作用,如微小核糖核酸(microRNA)海绵化、基因表达调控和信号通路干扰等,它们协调了驱动肝癌肿瘤发生、进展和耐药性的分子复杂性的一部分。它们在肝癌组织中的独特表达模式预示着早期检测 HCC 的新机遇,为了解患者预后提供了洞察力,并为这种疾病的治疗干预确定了新的靶点。这些进展凸显了假基因在丰富我们对 HCC 的认识和管理方面的重要性,为我们在与这种具有挑战性的恶性肿瘤的持续斗争中采用更有效的诊断策略和靶向疗法铺平了道路。
{"title":"Transforming 'Junk' DNA into Cancer Warriors: The Role of Pseudogenes in Hepatocellular Carcinoma.","authors":"Chugh Kritika","doi":"10.21873/cdp.10311","DOIUrl":"https://doi.org/10.21873/cdp.10311","url":null,"abstract":"<p><p>In the dynamic landscape of hepatocellular carcinoma (HCC) or the liver cancer research, pseudogenes have emerged from the shadows of genetic obscurity to become central figures, significantly influencing the disease molecular development and clinical trajectory. This review explores a transformative shift in perspective, recognizing pseudogenes not as genetic remnants without function, but as critical regulators in the molecular underpinnings of HCC. Engaging in complex interactions such as microRNA sponging, gene expression modulation, and signaling pathway disruptions, pseudogenes orchestrate a part of the molecular complexity driving tumor genesis, progression, and drug resistance in the liver cancer. Their unique expression patterns in hepatoma tissues herald new opportunities for early HCC detection, offering insights into patient prognosis, and identifying novel targets for therapeutic intervention of this disease. Such advancements underscore the importance of pseudogenes in enriching our understanding and management of HCC, paving the way for more effective diagnostic strategies and targeted therapies in the ongoing battle against this challenging malignancy.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region. 现实世界中农村地区转移性肾细胞癌患者接受系统治疗的相关因素。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10316
Carsten Nieder, Luka Stanisavljevic, Ellinor Christin Haukland

Background/aim: Numerous new treatment options have been approved for metastatic renal cell carcinoma (mRCC) in the last decade. Nevertheless, not all patients receive systemic therapy. Certain patients present with very advanced disease, poor Eastern Cooperative Oncology Group performance status (ECOG PS), or severe comorbidity, i.e. factors that lead oncologists to prefer best supportive care (BSC) instead of systemic therapy. The aim of this quality-of-care study was to identify baseline factors (disparities) associated with receipt of systemic therapy rather than BSC.

Patients and methods: This retrospective analysis included 140 consecutive patients managed in a rural region of Norway (2007-2022). Two differently managed groups were compared in univariate tests followed by multi-nominal regression.

Results: The majority of patients (n=95, 68%) had received systemic therapy. Typical patients were males in their 60s or 70s, with clear cell histology, prior nephrectomy, and intermediate prognostic features. Patients who received systemic therapy lived significantly longer than those who did not (median 30.4 versus 5.0 months, p<0.001). Survival benefit of systemic treatment was observed even in patients with ECOG PS3 or age ≥80 years. In addition to younger age (p<0.001) and better ECOG PS (p<0.001), metachronous presentation was associated with higher rates of systemic therapy utilization (p=0.03).

Conclusion: Assignment to systemic therapy for mRCC was individualized in the present patient population. In all age and ECOG PS subgroups, systemic therapy was associated with better survival (doubling at least). Optimum utilization rates are difficult to determine. However, in light of the survival outcomes, a rate of 12% in patients aged 80 years or older appears rather low.

背景/目的:在过去十年中,转移性肾细胞癌(mRCC)已获批许多新的治疗方案。然而,并非所有患者都能接受系统治疗。某些患者的病情已到晚期、东部合作肿瘤学组(Eastern Cooperative Oncology Group)治疗效果不佳(ECOG PS)或合并症严重,这些因素导致肿瘤专家倾向于选择最佳支持治疗(BSC)而非全身治疗。这项护理质量研究旨在确定与接受系统治疗而非 BSC 相关的基线因素(差异):这项回顾性分析包括在挪威农村地区接受治疗的 140 名连续患者(2007-2022 年)。通过单变量检验比较了两组不同的治疗方案,然后进行了多项式回归:大多数患者(95人,68%)接受过系统治疗。典型患者为六七十岁的男性,组织学为透明细胞,既往接受过肾切除术,预后处于中等水平。接受系统治疗的患者的生存期明显长于未接受系统治疗的患者(中位数分别为30.4个月和5.0个月,p):在本研究的患者群体中,mRCC的全身治疗是个体化的。在所有年龄组和 ECOG PS 亚组别中,系统性治疗都能提高生存率(至少翻倍)。最佳使用率很难确定。不过,从生存结果来看,80 岁或以上患者 12% 的使用率似乎相当低。
{"title":"Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region.","authors":"Carsten Nieder, Luka Stanisavljevic, Ellinor Christin Haukland","doi":"10.21873/cdp.10316","DOIUrl":"https://doi.org/10.21873/cdp.10316","url":null,"abstract":"<p><strong>Background/aim: </strong>Numerous new treatment options have been approved for metastatic renal cell carcinoma (mRCC) in the last decade. Nevertheless, not all patients receive systemic therapy. Certain patients present with very advanced disease, poor Eastern Cooperative Oncology Group performance status (ECOG PS), or severe comorbidity, i.e. factors that lead oncologists to prefer best supportive care (BSC) instead of systemic therapy. The aim of this quality-of-care study was to identify baseline factors (disparities) associated with receipt of systemic therapy rather than BSC.</p><p><strong>Patients and methods: </strong>This retrospective analysis included 140 consecutive patients managed in a rural region of Norway (2007-2022). Two differently managed groups were compared in univariate tests followed by multi-nominal regression.</p><p><strong>Results: </strong>The majority of patients (n=95, 68%) had received systemic therapy. Typical patients were males in their 60s or 70s, with clear cell histology, prior nephrectomy, and intermediate prognostic features. Patients who received systemic therapy lived significantly longer than those who did not (median 30.4 versus 5.0 months, p<0.001). Survival benefit of systemic treatment was observed even in patients with ECOG PS3 or age ≥80 years. In addition to younger age (p<0.001) and better ECOG PS (p<0.001), metachronous presentation was associated with higher rates of systemic therapy utilization (p=0.03).</p><p><strong>Conclusion: </strong>Assignment to systemic therapy for mRCC was individualized in the present patient population. In all age and ECOG PS subgroups, systemic therapy was associated with better survival (doubling at least). Optimum utilization rates are difficult to determine. However, in light of the survival outcomes, a rate of 12% in patients aged 80 years or older appears rather low.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer diagnosis & prognosis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1